Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Avandia to Remain Available in the US: GSK
August 20, 2007
- Korosho Starts Drafting New Vision for Medical Device Industry
August 20, 2007
- SURVEY／Once-Daily Bisphosphonate Formulations Preferred to Once-Weekly Formulations
August 20, 2007
- SURVEY／Majority of Users Do not Obtain Viagra from Hospitals
August 6, 2007
- Kyowa Hakko Licenses New Antibody Engineering Technology to BioWa
August 6, 2007
- Merck to Acquire NovaCardia
August 6, 2007
- R&D NEWS IN BRIEF
August 6, 2007
- Eisai Licenses Eszopiclone from Sepracor
August 6, 2007
- Elmed Eisai Conducts PMS on 2 of Its Generic Products
August 6, 2007
- Kissei Enters into Agreement with Nuon Therapeutics on Rizaben
August 6, 2007
- GENERICS NEWS IN BRIEF
August 6, 2007
- Mitsubishi Tanabe to Start Domestic Sales with 15 Branches, 142 Business Offices
August 6, 2007
- Transnasal Endoscopy IT Forum to Start Full-Scale Activities
August 6, 2007
- NEW PRODUCTS／Flivas OD Tablet 75 mg: Asahi Kasei Pharma
August 6, 2007
- Incidence of Nasal Bleeding 6% in Transnasal Endoscopy
August 6, 2007
- Nippon Kayaku to Consolidate Its Position as Specialty Pharma Focusing on Oncology
August 6, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 6, 2007
- Astellas, Pfizer Initiate Campaign on Prevention of Arteriosclerosis
August 6, 2007
- Use IT to More Effectively Use Patients' Data: AstraZeneca President Dr Kato
August 6, 2007
- Korosho Wants to See 1/4-1/3 of World's New Drugs Developed in Japan: New Industry Vision
August 6, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…